Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “19 and 22+ B Cell Hematologic Tumors”

2 trials

Showing 2 of 2 results

Early research (Phase 1)Looking for participantsNCT05388695
What this trial is testing

To Observe the Dual-target Chimeric Antigen Receptor T Cells in the Treatment of B Cell Hematologic Tumors

Who this might be right for
19 and 22+ B Cell Hematologic Tumors19 and 20+ B Cell Hematologic Tumors
Hebei Senlang Biotechnology Inc., Ltd. 100
Testing effectiveness (Phase 2)UnknownNCT03614858
What this trial is testing

CD19/CD22-targeted Chimeric Antigen Receptor Engineered T Cell (CART) in B-Cell Acute Lymphoblastic Leukemia.

Who this might be right for
Leukemia, B-cell
Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd 20

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation